#USA #San Diego #QuidelOrtho #prenatal care #Allo Hope

QuidelOrtho and Allo Hope Foundation Collaborate

In a groundbreaking partnership, QuidelOrtho, a leader in diagnostic innovation, has joined forces with the Allo Hope Foundation, a nonprofit organization dedicated to supporting families and medical professionals facing maternal alloimmunization. This collaboration aims to enhance prenatal care through improved education, early testing, and fostering stronger connections between laboratory providers, clinicians, and patients.

Alloimmunization is a complex condition that arises when a pregnant woman develops antibodies against the blood cells of her fetus. This can lead to serious health risks for the infant, including hemolytic disease of the fetus and newborn (HDFN). The condition often remains inadequate to understand for families, especially those from underserved backgrounds, leading to critical gaps in care.

Through this partnership, QuidelOrtho and Allo Hope aim to bridge these gaps. Their joint efforts will focus on developing educational resources that give voice to patients, raise awareness among healthcare providers, and guarantee that women receive informed and equitable prenatal testing and care from the outset of their pregnancy.

Bryan Hanson, Executive Vice President at QuidelOrtho, emphasized the importance of this partnership, stating, "At QuidelOrtho, our mission is to advance diagnostics for a healthier future for all. By collaborating with the Allo Hope Foundation, we are activating that mission in a significant new way, ensuring that alloimmunized patients receive the early testing, accurate information, and compassionate support they deserve."

Bethany Weathersby, the Founder and Executive Director of Allo Hope, echoed this sentiment, highlighting the foundation’s commitment to placing the patient experience at the forefront. "Families facing alloimmunization often feel overwhelmed and isolated. This collaboration allows us to combine clinical expertise, trusted diagnostics, and personal experiences to provide educational materials that resonate with compassion and clarity."

Beginning this summer, QuidelOrtho and Allo Hope will roll out a series of co-developed educational materials tailored for laboratory technicians and families alike. These resources will be accessible through both organizations' digital platforms, ensuring wider reach and impact.

QuidelOrtho is known for its relentless pursuit of innovation in diagnostics, offering comprehensive testing solutions that improve patient outcomes. With a broad spectrum of capabilities in clinical chemistry, immunoassay, immunohematology, and molecular testing, QuidelOrtho stands at the forefront of the diagnostic industry (Nasdaq QDEL).

Meanwhile, the Allo Hope Foundation is dedicated to supporting families and clinicians worldwide navigating the complexities of red cell alloimmunization and HDFN. With a team comprising patients with expertise in education, research, and clinical practice, AHF strives to make survival from HDFN not just a possibility but an expectation across the globe. The foundation actively provides counsel to families, facilitates specialty referrals, and conducts clinical research to empower families and enhance public health initiatives.

This partnership represents not just a merging of resources, but a shared mission to amplify awareness about alloimmunization while creating a supportive environment for families facing it. Together, QuidelOrtho and the Allo Hope Foundation are paving the way for improved prenatal care outcomes and ensuring that every family has access to the information and support they need during one of the most critical times in their lives.